The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys

Vaccine

Volumn 16, Issue 13, 1998, Pages 1324-1330

  Durbin, Anna P ^a   Wyatt, Linda S ^a   Siew, Jeffrey ^a   Moss, Bernard ^a   Murphy, Brian R ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

MVA F recombinant; MVA HN recombinant; Parainfluenza virus type 3

Indexed keywords

HN PROTEIN; HYBRID PROTEIN; LIVE VACCINE; RECOMBINANT VACCINE; VACCINIA VACCINE; VIRUS GLYCOPROTEIN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HOST RESISTANCE; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRATRACHEAL DRUG ADMINISTRATION; LOWER RESPIRATORY TRACT; LUNG LAVAGE; NONHUMAN; NOSE SECRETION; PARAINFLUENZA VIRUS 3; PARENTERAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RHESUS MONKEY; UPPER RESPIRATORY TRACT; VACCINIA VIRUS; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS RESISTANCE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; CHICK EMBRYO; HN PROTEIN; INJECTIONS, INTRAMUSCULAR; MACACA MULATTA; PARAINFLUENZA VIRUS 3, HUMAN; RESPIROVIRUS INFECTIONS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VACCINIA VIRUS; VIRAL FUSION PROTEINS; VIRAL VACCINES;

EID: 0032145732     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00010-3     Document Type: Article

References (36)

1. 1 Murphy, B.R., Prince, G.A. and Collins, P.L. et al. Current approaches to the development of vaccines effective against parainfluenza and respiratory syncytial viruses. Virus Res. 1988, 11, 1-15.
2. 2 Collins, P.L., McIntosh, K. and Chanock, R.M. Respiratory syncytial virus. In: Fields Virology (Eds Fields, B.N., Knipe, D.M., Howley, P.M. et al.), 3rd edn. Lippincott-Raven, Philadelphia, 1996, Vol. 2, pp. 1313 1352.
3. 3 Reed, G., Jewett, P.M., Thompson, J., Tollefson, S. and Wright, P.F. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children <5 years old. J. Infect. Dis. 1997, 175, 807-813.
4. 4 Belshe, R.B., Karron, R.A. and Newman, F.K. et al. Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children. J. Clin. Microbiol. 1992, 30, 2064-2070.
5. 5 Karron, R.A., Wright, P.F. and Newman, F.K. et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J. Infect. Dis. 1995, 172, 1445 1450.
6. 6 Karron, R.A., Wright, P.F. and Hall, S.L. et al. A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J. Infect. Dis. 1995, 171, 1107-1114.
7. 7 Crowe, J.E. Jr, Collins, P.L., Chanock, R.M. and Murphy, B.R. Vaccines against respiratory syncytial virus and parainfluenza virus type 3. In: New Generation Vaccines (Eds Levine, M.M., Woodrow, G.C., Kaper, J.B. and Cobon, G.S.), 2nd edn. Marcel Dekker, New York, 1997, pp. 711-725.
8. 8 Spriggs, M.K., Murphy, B.R., Prince, G.A., Olmsted, R.A. and Collins, P.L. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity. J. Virol. 1987, 61, 3416-3423.
9. 9 Spriggs, M.K., Collins, P.L., Tierney, E., London, W.T. and Murphy, B.R. Immunization with vaccinia virus recombinants that express the surface glycoproteins of human parainfluenza virus type 3 (PIV3) protects patas monkeys against PIV3 infection. J. Virol. 1988, 62, 1293-1296.
10. 10 Fenner, F., Henderson, D.A., Arita, I., Kezek, Z. and Ladnyi, I.D. Smallpox and its Eradication. World Health Organization, Geneva, 1988.
11. 11 Redfield, R.R., Wright, D.C., James, W.D., Jones, T.S., Brown, C. and Burke, D.S. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N. Engl. J. Med. 1987, 316, 673 676.
12. 12 Mayr, A., Hochstein-Mintzel, V. and Stickl, H. Passage history, properties, and applicibility of the attenuated vaccinia virus strain MVA. Infection 1975, 3, 6-14.
13. 13 Meyer, H., Sutter, G. and Mayr, A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 1991, 72, 1031-1038.
14. 14 Sutter, G. and Moss, B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 10847-10851.
15. 15 Carroll, M.W. and Moss, B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 1997, 238, 198-211.
16. 16 Sutter, G., Wyatt, L.S., Foley, P.L., Bennink, J.R. and Moss, B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994, 12, 1032-1040.
17. 17 Werner, G.T., Jentzsch, U., Metzger, E. and Simon, J. Studies on Poxvirus infections in irradiated animals. Arch. Virol. 1980, 64, 247-256.
18. 18 Stickl, H., Hochstein-Mintzel, V., Mayr, A., Huber, H.C., Schafer, H. and Holzner, A. [MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)]. Dtsch Med. Wochenschr. 1974, 99, 2386-2392.
19. 19 Mayr, A., Stickl, H., Muller, H.K., Danner, K. and Singer, H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl. Bakteriol. [B] 1978, 167, 375-390.
20. 20 Wyatt, L.S., Shors, S.T., Murphy, B.R. and Moss, B. Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infeciton in an animal model. Vaccine 1996, 14, 1451-1458.
21. 21 Murphy, B.R., Olmsted, R.A., Collins, P.L., Chanock, R.M. and Prince, G.A. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses. J. Virol. 1988, 62, 3907-3910.
22. 22 Murphy, B.R., Collins, P.L., Lawrence, L., Zubak, J., Chanock, R.M. and Prince, G.A. Immunosuppression of the antibody response to respiratory syncytial virus (RSV) by pre-existing serum antibodies: partial prevention by topical infection of the respiratory tract with vaccinia virus-RSV recombinants. J. Gen. Virol. 1989, 70, 2185-2190.
23. 23 Galletti, R., Beauverger, P. and Wild, T.F. Passively administered antibody suppresses the induction of measles virus antibodies by vaccinia-measles recombinant viruses. Vaccine 1995, 13, 197-201.
24. 24 van Binnendijk, R.S., Poelen, M.C., van Amerongen, G., de Vries, P. and Osterhaus, A.D. Protective immunity in macaques vaccinated with live attenuated, recombinant, and subunit measles vaccines in the presence of passively acquired antibodies. J. Infect. Dis. 1997, 175, 524-532.
25. 25 Bender, B.S., Rowe, C.A., Taylor, S.F., Wyatt, L.S., Moss, B. and Small, P.A. Jr.Jr Oral immunization with a replicationdeficient recombinant vaccinia virus protects mice against influenza. J. Virol. 1996, 70, 6418-6424.
26. 26 Belshe, R.B. and Hissom, F.K. Cold adaptation of parainfluenza virus type 3: induction of three phenotypic markers. J. Med. Virol 1982, 10, 235-242.
27. 27 Murphy, B.R., Richman, D.D., Chalhub, E.G., Uhlendorf, C.P., Baron, S. and Chanock, R.M. Failure of attenuated temperature-sensitive influenza A (H3N2) virus to induce heterologous interference in humans to parainfluenza type 1 virus. Infect. Immun. 1975, 12, 62-68.
28. 28 Hall, S.L., Stokes, A. and Tierney, E.L. et al. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res. 1992, 22, 173-184.
29. 29 Coelingh, K.J., Winter, C.C. and Murphy, B.R. et al. Conserved epitopes on the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: nucleotide sequence analysis of variants selected with monoclonal antibodies. J. Virol. 1986, 60, 90-96.
30. 30 Flexner, C., Murphy, B.R. and Rooney, J.F. et al. Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen. Nature 1988, 335, 259-262.
31. 31 Connors, M., Collins, P.L. and Firestone, C.Y. et al. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia - RSV recombinants or RSV. Vaccine 1992, 10, 475-484.
32. 32 Murphy, B.R. (Ed.) Mucosal Immunity to Viruses. Academic Press, New York, 1993. [Ogra, P.A., Mestecky, J., Lamm, M., Strober, W., McGhee, J., Bienstock, J. (Eds) Mucosal Immunology: Vol. I Cellular Basis of Mucosal Immunity.]
33. 32 Murphy, B.R. (Ed.) Mucosal Immunity to Viruses. Academic Press, New York, 1993. [Ogra, P.A., Mestecky, J., Lamm, M., Strober, W., McGhee, J., Bienstock, J. (Eds) Mucosal Immunology: Vol. I Cellular Basis of Mucosal Immunity.]
34. 33 Takao, S.I., Kiyotani, K., Sakaguchi, T., Fujii, Y., Seno, M. and Yoshida, T. Protection of mice from respiratory Sendai virus infections by recombinant vaccinia viruses. J. Virol. 1997, 71, 832-838.
35. 34 Brehm, M.A., Bonneau, R.H., Knipe, D.M. and Tevethia, S.S. Immunization with a replication-deficient mutant of herpes simplex virus type 1 (HSV-1) induces a CD8+ cytotoxic T-lymphocyte response and confers a level of protection comparable to that of wild-type HSV-1. J. Virol. 1997, 71, 3534-3544.
36. 35 Mittal, S.K., Papp, Z. and Tikoo, S.K. et al. Induction of systemic and mucosal immune responses in cotton rats immunized with human adenovirus type 5 recombinants expressing the full and truncated forms of bovine herpesvirus type 1 glycoprotein gD. Virology 1996, 222, 299-309.